Market Cap
$11.6B
BMRN
BIOMARIN PHARMACEUTICAL INC
$57.18 ▼ -2.16%
Prev close $58.44Market cap$11.6B
ConsensusBuy
12-mo target$91.62 (+60.2%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)31 New Institutional Positions19 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on BMRN right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (77%)
Inst. Holders
50 funds
Inst. Value
$8.5B
Inst. Activity
31 buys / 19 sells
Insider Activity
$0.00 buy / $4.3M sell
Insider Net $
-$4.3M
SEC Reports
10
Press Releases
1
Price chart 30d -13.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Feb 28, 2027 fda_pdufa
PDUFA: BMRN — VOXZOGO in achondroplasia — 2027-02-28
FDA target action date 2027-02-28 for BMRN (BIOMARIN PHARMACEUTICAL INC). Drug: VOXZOGO. Indication:
Sep 30, 2026 Insider
Sep 15, 2026 SEC Friberg Gregory R surrendered for taxes 4,086 shares
EVP, Chief R&D Officer @ $60.00 ($245.2K)
BioMarin discontinued development of VOXZOGO for Noonan syndrome, citing feasibility and the current treatment landscape
8-K — Impact 4/10
BioMarin appointed Robert Plenge, M.D., Ph.D., to its Board of Directors, expanding the board from ten to eleven members
8-K — Impact 2/10
Sep 10, 2026 Insider
Plenge Robert M was granted 6,140 shares
Director
Sep 2, 2026 Insider
Sep 1, 2026 SEC Davis George Eric sold 17,557 shares
EVP, Chief Legal Officer @ $66.28 ($1.2M)
BioMarin completed its previously announced acquisition of Alesta Therapeutics B.V. on August 31, 2026, making Alesta a
8-K — Impact 3/10
BioMarin completed its acquisition of Alesta Therapeutics, adding ALE1, a Phase 1/2a oral small-molecule candidate for h
Impact 4/10
Analyst ratings buy % -1.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
77% rate it Buy or better · 35 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 10, 2026 | HC Wainwright & Co. | REITERATE | Neutral | 43% |
| Sep 1, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Aug 31, 2026 | Jefferies | MAINTAIN | Buy | 53% |
| Aug 31, 2026 | HC Wainwright & Co. | MAINTAIN | Neutral | 43% |
| Aug 19, 2026 | BMO Capital | INITIATE | Outperform | 53% |
| Aug 18, 2026 | HC Wainwright & Co. | MAINTAIN | Neutral | 43% |
| Aug 17, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Aug 17, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Aug 10, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Aug 7, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 10 | 17 | 8 | 0 | 0 | 77% | |
| Aug 1, 2026 | 10 | 16 | 7 | 0 | 0 | 79% | |
| Jul 1, 2026 | 11 | 16 | 7 | 0 | 0 | 79% | |
| Jun 1, 2026 | 11 | 16 | 7 | 0 | 0 | 79% | |
| May 1, 2026 | 10 | 16 | 6 | 0 | 0 | 81% | |
| Apr 1, 2026 | 10 | 15 | 6 | 0 | 0 | 81% | |
| Mar 1, 2026 | 9 | 16 | 7 | 0 | 0 | 78% | |
| Feb 1, 2026 | 9 | 16 | 7 | 0 | 0 | 78% |
Price targets
Where 26 covering analysts think BMRN trades over the next 12 months.
$91.62 +60.2% upside Strong Buy
Current$57.18 Low$60.00 Median$90.00 High$124.00 26 analysts
$60.00$124.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
10 SEC filing reports analyzed · 3 bullish, 0 bearish, 1 mixed, 6 neutral · avg impact 4.4/10.Plus 1 press releases.
NEUTRAL8-K4/10
BioMarin discontinued development of VOXZOGO for Noonan syndrome, citing feasibility and the current
Sep 15, 2026
NEUTRAL8-K2/10
BioMarin appointed Robert Plenge, M.D., Ph.D., to its Board of Directors, expanding the board from t
Sep 14, 2026
NEUTRAL8-K3/10
BioMarin completed its previously announced acquisition of Alesta Therapeutics B.V. on August 31, 20
Sep 1, 2026
BULLISH8-K6/10
BioMarin entered a binding term sheet with Ascendis Pharma to settle all global patent litigation. A
Aug 31, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Feb 28, 2027
fda_pdufa
PDUFA: BMRN — VOXZOGO in achondroplasia — 2027-02-28
FDA target action date 2027-02-28 for BMRN (BIOMARIN PHARMACEUTICAL INC). Drug: VOXZOGO. Indication: achondroplasia. FDA accepted sNDA for full approv
Oct 2, 2026
other
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/
Oct 1, 2026
Clinical Trial
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
Phase Phase 3 — TERMINATED
Sep 30, 2026
short_volume
Short Volume: BMRN — 60.6% short (0.3M / 0.5M)
Short: 333,075 | Exempt: 31 | TRF Vol: 549,434 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: BMRN — 56.2% short (0.4M / 0.7M)
Short: 388,547 | Exempt: 75 | TRF Vol: 690,874 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $1.25 | $0.17–$1.48 | 937.9% | -9.6% | 0↑ 12↓ | $1.0B | 14 |
| Next Q | $1.75 | $1.63–$1.93 | 280.9% | +0.9% | 7↑ 5↓ | $1.1B | 15 |
| Current FY | $4.94 | $3.79–$5.07 | 56.9% | -1.7% | 13↑ 1↓ | $3.9B | 18 |
| Next FY | $6.62 | $5.64–$7.66 | 34.0% | +1.4% | 9↑ 4↓ | $4.5B | 18 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.246 | — |
| 7d ago | $1.339 | -0.093 |
| 30d ago | $1.378 | -0.132 |
| 60d ago | $1.490 | -0.245 |
| 90d ago | $1.488 | -0.243 |
Institutional ownership
Which big funds own BMRN (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $8.5B total value (148,982,044 shares) as of 2026-Q2. Top holders: BlackRock,, DODGE, PRIMECAP. Net buying activity: 31 institutions added/increased vs 19 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 20,445,212 | $1.2B | 13.7% | — |
| DODGE & COX | 14,844,930 | $849.4M | 10.0% | — |
| PRIMECAP MANAGEMENT CO/CA/ | 14,190,183 | $812.0M | 9.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 8,743,633 | $500.3M | 5.9% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 8,648,678 | $494.9M | 5.8% | — |
| NORGES BANK | 8,207,954 | $469.7M | 5.5% | NEW |
| STATE STREET CORP | 7,800,959 | $446.4M | 5.2% | — |
| VIKING GLOBAL INVESTORS LP | 7,616,563 | $435.8M | 5.1% | — |
| AQR CAPITAL MANAGEMENT LLC | 5,699,541 | $322.5M | 3.8% | — |
| FMR LLC | 4,822,893 | $276.0M | 3.2% | ADD +35.2% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 8,207,954 | — | $469.7M |
| FMR LLC | ADD | 3,567,031 | 4,822,893 | +35.2% | $276.0M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 3,010,308 | 2,071,816 | -31.2% | $118.5M |
| Swedbank AB | ADD | 792,187 | 1,314,787 | +66.0% | $75.2M |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | ADD | 945,603 | 1,236,446 | +30.8% | $70.7M |
| GOLDMAN SACHS GROUP INC | DOUBLED | 379,596 | 1,201,977 | +216.6% | $68.8M |
| CITADEL ADVISORS LLC | NEAR_EXIT | 4,512,634 | 1,122,408 | -75.1% | $64.2M |
| MACKENZIE FINANCIAL CORP | DOUBLED | 441,444 | 931,864 | +111.1% | $53.3M |
| Russell Investments Group, Ltd. | ADD | 606,224 | 783,148 | +29.2% | $44.8M |
| LOS ANGELES CAPITAL MANAGEMENT LLC | ADD | 407,379 | 696,784 | +71.0% | $39.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
16 insiders, 48 transactions. Net -$4.3M — $0.00 bought, $4.3M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Friberg Gregory R | EVP, Chief R&D Officer | TAX W/H | 4,086 | $60.00 | $245.2K |
| Sep 10, 2026 | Plenge Robert M | Director | AWARD | 6,140 | — | — |
| Sep 2, 2026 | Davis George Eric | EVP, Chief Legal Officer | SELL | 17,557 | $66.28 | $1.2M |
| Jun 2, 2026 | Ho Maykin | Director | AWARD | 7,490 | — | — |
| Jun 2, 2026 | ANDERSON ELIZABETH M | Director | AWARD | 7,490 | — | — |
| Jun 2, 2026 | CLARK IAN T | Director | AWARD | 7,490 | — | — |
| Jun 2, 2026 | Bodem Barbara W. | Director | AWARD | 7,490 | — | — |
| Jun 2, 2026 | Dere Willard H | Director | AWARD | 7,490 | — | — |
| Jun 2, 2026 | HOMBACH ROBERT J. | Director | AWARD | 7,490 | — | — |
| Jun 2, 2026 | Enyedy Mark J | Director | AWARD | 7,490 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for BMRN.
Shares short
10,075,655
Settlement Sep 15, 2026
Change vs prior
+2.0%
Semi-monthly cycle
Days to cover
5.5
At avg daily volume
Of shares outstanding
≈5.2%
Estimate — not % of float
All BMRN filing & press-release reports (11)
- 8-K reportSep 15, 2026
- 8-K reportSep 14, 2026
- 8-K reportSep 1, 2026
- PRESS-RELEASE reportSep 1, 2026
- 8-K reportAug 31, 2026
- 8-K reportAug 18, 2026
- 8-K reportJun 4, 2026
- 8-K reportApr 27, 2026
- DEFA14A reportApr 21, 2026
- INST-CLUSTER reportFeb 28, 2026
- CLUSTER reportFeb 27, 2026